Etakafusp alfa
Highest phase reached
Phase 2
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Protein
- Drug name
- Etakafusp alfa
- ab 248
- AB-248
- ab248
- Ab248
- AB248
- etakafusp alfa
- Etakafusp alfa
- etakafusp alfa (AB248)
- etakafusp alfa [INN]
- ETAKAFUSP ALFA [USAN]
- Etakafusp alfa [WHO-DD]
- etakafusp alfa inn
- etakafusp alfa usan
- etakafusp alfa who dd
- gamma 1 heavy chain (1-448) [VH (Homo sapiens IGHV1-69*01 -(IGHD) -IGHJ4*01, CDR-Kabat [5.17.10] (31-35.50-66.99-108)) (1-119) -Homo sapiens IGHG1*03v (CH1 (120-217), hinge (218-232), CH2 L <sup>236</sup> >A, L <sup>237</sup> >A, G<sup>239</sup> >A (233-342), CH3 S <sup>356</sup> >C, T<sup>368</sup> >S, L <sup>370</sup> >A, Y <sup>409</sup> >V (343-447), CHS K <sup>449</sup> >del (448)) (120-448)] fused via a peptide linker <sup>449</sup> SGGGGSGGGGSGGGGS <sup>464</sup> to human interleukin-2 (IL-2, T-cell growth factor (TCGF) fragment 21-153, [H <sup>36</sup> >E <sup>480</sup> , R<sup>58</sup> >E <sup>502</sup> , F <sup>62</sup> >A <sup>506</sup> , C<sup>145</sup> >A <sup>589</sup> ]-variant (1-133, 465-597 in the current sequence), (222-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 -IGKJ4*01, CDR-Kabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (108'-214')]; (228-228'':231-231'':356-351'')-trisdisulfide with gamma 1 heavy chain (1''-449'') [VH (Homo sapiens IGHV1-69*01 -(IGHD) -IGHJ4*01, CDR-Kabat [5.17.10] (31''-35''.50''-66''.99''-108'')) (1''-119'') -Homo sapiens IGHG1*03v (CH1 (120''-217''), hinge (218''-232''), CH2 L <sup>236''</sup> >A, L <sup>237''</sup> >A, G<sup>239''</sup> >A (233''-342''), CH3 Y <sup>351''</sup> >C, T<sup>368''</sup> >W (343''-447''), CHS (448''-449'')) (120''-449'')], (222''-214''')-disulfide with kappa light chain (1'''-214''') [V-KAPPA (Homo sapiens IGKV1-39*01 -IGKJ4*01, CDR-Kabat [11.7.9] (24'''-34'''.50'''-56'''.89'''-97''')) (1'''-107''') -Homo sapiens IGKC*01 (108'''-214''')]; produced in Chinese hamster ovary (CHO) cells, glycoform alfa antineoplastic
- gamma 1 heavy chain 1 448 vh homo sapiens ighv1 69 01 ighd ighj4 01 cdr kabat 5 17 10 31 35 50 66 99 108 1 119 homo sapiens ighg1 03v ch1 120 217 hinge 218 232 ch2 l sup 236 sup a l sup 237 sup a g sup 239 sup a 233 342 ch3 s sup 356 sup c t sup 368 sup s l sup 370 sup a y sup 409 sup v 343 447 chs k sup 449 sup del 448 120 448 fused via a peptide linker sup 449 sup sggggsggggsggggs sup 464 sup to human interleukin 2 il 2 t cell growth factor tcgf fragment 21 153 h sup 36 sup e sup 480 sup r sup 58 sup e sup 502 sup f sup 62 sup a sup 506 sup c sup 145 sup a sup 589 sup variant 1 133 465 597 in the current sequence 222 214 disulfide with kappa light chain 1 214 v kappa homo sapiens igkv1 39 01 igkj4 01 cdr kabat 11 7 9 24 34 50 56 89 97 1 107 homo sapiens igkc 01 108 214 228 228 231 231 356 351 trisdisulfide with gamma 1 heavy chain 1 449 vh homo sapiens ighv1 69 01 ighd ighj4 01 cdr kabat 5 17 10 31 35 50 66 99 108 1 119 homo sapiens ighg1 03v ch1 120 217 hinge 218 232 ch2 l sup 236 sup a l sup 237 sup a g sup 239 sup a 233 342 ch3 y sup 351 sup c t sup 368 sup w 343 447 chs 448 449 120 449 222 214 disulfide with kappa light chain 1 214 v kappa homo sapiens igkv1 39 01 igkj4 01 cdr kabat 11 7 9 24 34 50 56 89 97 1 107 homo sapiens igkc 01 108 214 produced in chinese hamster ovary cho cells glycoform alfa antineoplastic
- humanized immunoglobulin g1 kappa anti human cd8 fused at the c terminus of one heavy chain via peptide linker 449sggggsggggsggggs464 to a variant of human interleukin 2 glycoform alfa gamma 1 heavy chain 1 448 vh homo sapiens ighv1 69 01 ighd ighj4 01 cdr kabat 5 17 10 31 35 50 66 99 108 1 119 homo sapiens ighg1 03v ch1 120 217 hinge 218 232 ch2 l236 a l237 a g239 a 233 342 ch3 s356 c t368 s l370 a y409 v 343 447 chs k449 del 448 120 448 fused via a peptide linker 449sggggsggggsggggs464 to human interleukin 2 il 2 t cell growth factor tcgf fragment 21 153 h16 e480 r38 e502 f42 a506 c125 a589 variant 1 133 465 597 in the current sequence 222 214 disulfide with kappa light chain 1 214 v kappa homo sapiens igkv1 39 01 igkj4 01 cdr kabat 11 7 9 24 34 50 56 89 97 1 107 homo sapiens igkc 01 108 214 228 228 231 231 356 351 trisdisulfide with gamma 1 heavy chain 1 449 vh homo sapiens ighv1 69 01 ighd ighj4 01 cdr kabat 5 17 10 31 35 50 66 99 108 1 119 homo sapiens ighg1 03v ch1 120 217 hinge 218 232 ch2 l236 a l237 a g239 a 233 342 ch3 y351 c t368 w 343 447 chs 448 449 120 449 222 214 disulfide with kappa light chain 1 214 v kappa homo sapiens igkv1 39 01 igkj4 01 cdr kabat 11 7 9 24 34 50 56 89 97 1 107 homo sapiens igkc 01 108 214 produced in chinese hamster ovary cho cells glycoform alfa
- humanized immunoglobulin g1 kappa anti human cd8 fused at the c terminus of one heavy chain via peptide linker sup 449 sup sggggsggggsggggs sup 464 sup to a variant of human interleukin 2 glycoform alfa
- humanized immunoglobulin G1-kappa anti-(human CD8) fused at the C-terminus of one heavy chain, via peptide linker <sup>449</sup> SGGGGSGGGGSGGGGS<sup>464</sup>, to a variant of human interleukin-2, glycoform alfa
- Humanized immunoglobulin G1-kappa anti-(human CD8) fused at the C-terminus of one heavy chain, via peptide linker 449SGGGGSGGGGSGGGGS464, to a variant of human interleukin-2, glycoform alfa; gamma 1 heavy chain (1-448) [VH (Homo sapiens IGHV1-69*01 - (IGHD) -IGHJ4*01, CDR-Kabat [5.17.10] (31-35.50-66.99-108)) (1-119) -Homo sapiens IGHG1*03v (CH1 (120-217), hinge (218-232), CH2 L236>A, L237>A, G239>A (233-342), CH3 S356>C, T368>S, L370>A, Y409>V (343-447), CHS K449>del (448)) (120-448)] fused via a peptide linker 449SGGGGSGGGGSGGGGS464 to human interleukin-2 (IL-2, T-cell growth factor (TCGF) fragment 21-153, [H16>E480,R38>E502, F42>A506, C125>A589]-variant (1-133, 465-597 in the current sequence), (222-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 -IGKJ4*01, CDR-Kabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (108'-214')]; (228-228'':231-231'':356-351'')-trisdisulfide with gamma 1 heavy chain (1''-449'') [VH (Homo sapiens IGHV1-69*01 -(IGHD) -IGHJ4*01, CDR-Kabat [5.17.10] (31''-35''.50''-66''.99''-108'')) (1''-119'') -Homo sapiens IGHG1*03v (CH1 (120''-217''), hinge (218''-232''), CH2 L236''>A, L237''>A, G239''>A (233''-342''), CH3 Y351''>C, T368''>W (343''-447''), CHS (448''-449'')) (120''-449'')], (222''-214''')-disulfide with kappa light chain (1'''-214''') [V-KAPPA (Homo sapiens IGKV1-39*01 -IGKJ4*01, CDR-Kabat [11.7.9] (24'''-34'''.50'''-56'''.89'''-97''')) (1'''-107''') -Homo sapiens IGKC*01 (108'''-214''')]; produced in Chinese hamster ovary (CHO) cells, glycoform alfa
- Immunoglobulin G1 [236-alanine,237-alanine,239-alanine,356-cysteine,368-serine,370-alanine,409-valine,de-449-lysine], anti-(human CD8 antigen) (human-Mus musculus monoclonal AB248 γ1-chain) fusion protein with peptide linker ((SGGGG)3S) fusion protein with interleukin 2 [16-glutamic acid,38-glutamic acid,42-alanine,125-alanine] (human), (228→228′),(231→231′),(356→351′)-tris(disulfide) with immunoglobulin G1 [236-alanine,237-alanine,239-alanine,351-cysteine,368-tryptophan] anti-(human CD8 antigen) (human-Mus musculus γ1-chain), disulfide with human-Mus musculus monoclonal AB248 κ-chain, dimer
- immunoglobulin g1 236 alanine 237 alanine 239 alanine 356 cysteine 368 serine 370 alanine 409 valine de 449 lysine anti human cd8 antigen human mus musculus monoclonal ab248 γ1 chain fusion protein with peptide linker sgggg 3s fusion protein with interleukin 2 16 glutamic acid 38 glutamic acid 42 alanine 125 alanine human 228 228 231 231 356 351 tris disulfide with immunoglobulin g1 236 alanine 237 alanine 239 alanine 351 cysteine 368 tryptophan anti human cd8 antigen human mus musculus γ1 chain disulfide with human mus musculus monoclonal ab248 κ chain dimer
- CAS registry numbers
- 2852680-28-3
- ChEMBL ID
- CHEMBL6068121
- FDA ingredient codes (UNII)
- 5Y27P3LNU6
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -fusp
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005494
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain: IL2
- Type
- Protein
- Sequence
- QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPGYATANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDAAGIRLFADWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGSGGGGSGGGGSGGGGSAPTSSSTKKTQLQLEELLLDLQMILNGINNYKNPKLTEMLTAKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFAQSIISTLT
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 146-202 $ 146''-202'' $ 222-214' $ 222''-214''' $ 228-228'' $ 231-231'' $ 263-323 $ 263''-323'' $ 356-351'' $ 369-427 $ 369''-427'' $ 522-569
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSSLSASVGDRVTITCRASQSIYGALNWYQQKPGKAPKLLIYGASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQSTYTAPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPGYATANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDAAGIRLFADWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
- Component
- Glycosylation sites (N)
- Sequence
- 299 $ 299''
Related records
Trials (3)
- A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
- A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
- Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients
In development for (1)
- Neoplasm Phase 2